Best Canadian Stocks To Invest In Right Now

Related Banking Problems In The Cannabis Industry Are 'Somewhat Overblown In The Press' IAnthus CEO Talks About Raising Capital For U.S. Cannabis Companies In Canadian Markets And Marijuana Stocks To Watch

Earlier this month, cannabis-focused financing and advisory firm iAnthus Capital Holdings Inc (CNSX: IAN) (OTC: ITHUF) announced it acquired Westchester-based Valley Agriceuticals, LLC, gaining access to New York’s nascent cannabis market.

In an industry where few investments surpass seven figures, does a $17.3 million purchase make sense?

Best Canadian Stocks To Invest In Right Now: Silver Wheaton Corp(SLW)

Advisors’ Opinion:

  • [By Rich Duprey]

    Silver Wheaton (NYSE:SLW), of course, is a streamer like Sandstorm and Franco, but it is the largest in the precious-metals industry, and arguably the best-known, because its business model came to define what streaming is. Although it is known primarily for its silver contracts, Silver Wheaton also has sizable gold production that makes it worth your attention.

Best Canadian Stocks To Invest In Right Now: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

Best Canadian Stocks To Invest In Right Now: Credit Suisse Group(CS)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

  • [By Diane Alter]

    The head underwriters for the ZTO IPO are Morgan Stanley (NYSE: MS) and Goldman Sachs Group Inc. (NYSE: GS). Also working on the deal are China Renaissance, Citigroup Inc. (NYSE: C), Credit Suisse Group AG (NYSE ADR: CS), and JPMorgan Chase & Co. (NYSE: JPM).

  • [By David Zeiler]

    The federal government’s largesse isn’t restricted to U.S.-based companies, either. Foreign companies, including foreign banks, are also welcome. Credit Suisse Group AG (NYSE ADR: CS) got $225.1 billion, and UBS Group AG (NYSE: UBS) got $249.1 billion.

  • [By Money Morning News Team]

    That’s why Krauth predicts the price of gold will hit $1,400 by the end of the year. Many analysts from banks likeCredit SuisseGroup AG (NYSE ADR: CS) even see gold going as high as $1,500.

  • [By Wayne Duggan] Related DB Deutsche Bank In The Tank Mike Khouw Sees Unusual Options Activity In Deutsche Bank 33 Large Banks On The Federal Reserve's Radar In 2016 (Seeking Alpha)
    Related CS Earnings Scheduled For February 4, 2016 Blockchain Moves Forward In The Financial Industry Credit Suisse Group AG (CS) Tidjane Thiam on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    The latest credit default swap (CDS) data from BMO Capital Markets indicate a number of investors are growing increasingly concerned about the one-year outlook for capital markets. In a new report, analyst Mark Steele discussed the recent surge in one-year CDS activity, and what it means for the market.

Best Canadian Stocks To Invest In Right Now: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

Best Canadian Stocks To Invest In Right Now: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    After a horrible 2016, 2017 had started on a good note for shareholders of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX). With the rising optimism around the asset restructuring plan, VRX stock was up more than 10% in the first few days of the year. However, since then Valeant Pharma stock has lost its momentum. Valeant stock is down more than 25% YTD. Shares of the Laval, Qubecbased company were hit hard by the company’s disappointingguidance for 2017. Valeant stock is down by more than 35% since its latest earnings report on February 28th.

  • [By Lisa Levin]

    Breaking news

    Tiffany & Co. (NYSE: TIF) reported upbeat earnings for its fourth quarter on Friday.
    Adobe Systems Incorporated (NASDAQ: ADBE) reported better-than-expected results for its first quarter and issued a strong forecast for the current quarter.
    Tesla Inc (NASDAQ: TSLA) disclosed that it has priced its 1.34 million share common stock offering at $262 per share.
    Valeant Pharmaceuticals Intl Inc (NYSE: VRX) disclosed the purchase of 3 million shares by ValueAct — 500,000 shares of March 14, 2017 at $10.88 and the remaining 2.5 million shares at $10.81 per share.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.4% Monday to post a new 52-week low of $8.31 after closing Friday at $8.51. The stock’s 52-week high is $38.50. Volume of around 13.5 million shares was about 65% below the daily average of around 18.8 million. The company had no specific news, and shares are on track to add about 1.5% by the closing bell.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6.4% Wednesday to post a new 52-week low of $9.52 after closing Tuesday at $10.17. The stock’s 52-week high is $38.50. Volume of about 35 million shares was nearly double the daily average of around 19 million. The company is reportedly having trouble selling one of its division for what it deems an acceptable price.

  • [By WWW.KIPLINGER.COM]

    Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).

  • [By Sean Williams]

    Shares of Valeant Pharmaceuticals (NYSE:VRX), an embattled drug developer whose primary method of growth over the past couple of years has been via acquisitions and price hikes on its therapies, surged as much as 15% on Thursday for their third consecutive day of strong gains. The stock was up a more modest 9% as of the closing bell.

Best Canadian Stocks To Invest In Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

Leave a Reply

Your email address will not be published. Required fields are marked *